转自：成都日报锦观 天府中药城进军医疗器械产业新领域 本报讯 （成都日报锦观新闻记者 袁弘） 记者昨日获悉，彭州经开区企业艾立本科技完成A+轮融资， 加速提高全国产超高效液相色谱三重四极杆质谱联用仪市占率。这也成为2026年彭州经开区抢滩万亿医 疗器械新版图的"首作"。 作为四川省专精特新企业、国家级高新技术企业，艾立本科技此次完成的数千万元人民币A+轮融资， 由四川产业基金川创投交子梧桐基金领投，老股东四川发展彭州全球生物医药基金跟投。本轮融资资金 将主要用于艾立本自主正向研制的超高效液相色谱三重四极杆质谱联用仪的产能提升、市场推广及产品 升级等方面工作。 "面对全国园区在生命科学领域的同质化竞争，单纯的规模扩张已经难以持续，彭州经开区正将深厚的 中医药产业底蕴转化为在高端医疗器械赛道上的独特竞争力。彭州经开区相关负责人表示，通过构 建"研发—制造—应用"闭环，深化"药+械+数"融合发展，园区目前已经形成了以"中医诊疗设备、中药 源性医疗器械、智慧健康服务"为特色的产业生态，走出了一条兼具中药基因、彭州特色的医疗器械产 业发展之路。 ...

Core Insights - The National Medical Products Administration (NMPA) is focusing on supporting the innovative development of the biomanufacturing industry during the 14th Five-Year Plan period, transitioning from "follow-up innovation" to "systematic innovation" and from "scale-speed growth" to "quality-efficiency growth" [1] - In 2025, China approved 76 innovative drugs, showcasing its leading position in global R&D applications, with a trend towards complex frontier technologies, diversified innovation entities, and internationalized regulatory standards [1] - The medical device sector is also experiencing strong innovation, with 76 innovative medical devices approved in 2025, a 17% year-on-year increase, and a significant rise in priority approvals [1] Industry Developments - In 2026, the NMPA plans to strengthen drug safety risk management by enhancing risk prevention mechanisms and regulatory oversight across the entire drug clinical trial chain [2] - The focus will be on encouraging innovation while managing risks, particularly in the development of urgently needed drugs and the implementation of drug trial data protection systems [2] - The NMPA aims to improve the quality and efficiency of generic drug evaluations and strengthen post-marketing management of generic drugs [2] Regulatory Enhancements - The NMPA will enhance supervision of online drug sales and improve the drug information traceability system to increase risk management efficiency [2] - Specific attention will be given to new drug targets, AI-driven drug development, and cell and gene therapies, with expedited approval channels to accelerate the market entry of new and effective drugs [2]

Group 1 - The core point of the news is that southbound funds have been reducing their holdings in Qiming Medical-B (02500.HK), with a total net reduction of 97,000 shares over the last five trading days and 753,500 shares over the last twenty trading days [1][2] - As of February 5, 2026, southbound funds hold 52,175,600 shares of Qiming Medical-B, which accounts for 11.82% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show a consistent trend of reduction, with a decrease of 22,000 shares on February 5, 2026, and smaller reductions on previous trading days [2] Group 2 - Qiming Medical Co., Ltd. specializes in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices for treating heart valve diseases [2] - The company's product line includes devices for aortic, pulmonary, mitral, and tricuspid valve interventions, as well as systems for treating hypertrophic cardiomyopathy and renal denervation [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, and TriGUARD3 embolic protection device [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 153,800 shares on February 5, 2026, marking a decrease of 0.37% [1][2] - Over the past five trading days, there have been three days of net reductions by southbound funds, totaling 427,300 shares [1] - In the last twenty trading days, there were eleven days of net reductions, amounting to 2,033,000 shares [1] Group 2 - As of now, southbound funds hold 41,678,300 shares of Spring Medical, which represents 43.79% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as the hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [2]

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 23,200 shares on February 5, indicating a consistent trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the past 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 42,900 shares [1] - Over the last 20 trading days, southbound funds have reduced their holdings for all 20 days, resulting in a cumulative net reduction of 188,000 shares [1] - Currently, southbound funds hold 5,681,300 shares of Gaoshi Medical, accounting for 3.83% of the company's total issued ordinary shares [1] Group 2: Company Overview - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: proprietary products, distribution, technical services, and other services [1] - The proprietary products segment develops and produces surgical equipment, related software, intraocular lenses, and diagnostic and treatment devices for eye diseases [1]

截至2026年2月5日收盘，祥生医疗(688358)报收于35.6元，下跌0.95%，换手率0.85%，成交量9475.0 手，成交额3388.79万元。 当日关注点 交易信息汇总 无锡祥生医疗科技股份有限公司发布2025年前三季度权益分派实施公告，每股派发现金红利0.30元（含 税），以公司总股本112,125,613股为基数，合计派发现金红利33,637,683.90元。本次权益分派股权登记 日为2026年2月11日，除权（息）日为2026年2月12日，现金红利发放日为2026年2月12日。本次利润分 配不派送红股、不转增股本。部分股东的现金红利由公司自行发放，其余股东通过中国证券登记结算有 限责任公司上海分公司派发。根据股东性质不同，股息红利所得税按相关规定执行。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：2月5日主力资金净流出9.33万元，游资资金净流入195.43万元。 来自公司公告汇总：祥生医疗将于2026年2月12日实施2025年前三季度分红，每股派现0.30元（含 税）。 2月5日主力资金净流 ...

截至2026年2月5日收盘，维力医疗(603309)报收于14.57元，上涨1.25%，换手率1.79%，成交量5.22万 手，成交额7583.19万元。 当日关注点 交易信息汇总资金流向 来自交易信息汇总：2月5日主力资金净流出32.41万元，游资资金净流入37.05万元。 来自公司公告汇总：维力医疗多个产品获得欧盟MDR认证，具备在欧盟市场合法销售的准入条 件。 广州维力医疗器械股份有限公司于近日收到欧盟公告机构通知，公司多个产品获得欧盟MDR认证，包 括导尿管护理包、引流罐、穿刺导向器、微网雾化器、振动筛孔雾化器、冲水泵、泵管组件、胃管、人 工鼻、导引针、多通道内窥镜接头、导尿包、亲水乳胶导尿管、亲水硅胶导尿管、肾造瘘管、胃造瘘管 及营养管。认证证书由TÜV SÜD Product Service GmbH签发，签批时间为2026年2月3日，有效期至2028 年5月15日或2028年12月5日。上述产品获证表明其符合欧盟最新医疗器械法规要求，具备在欧盟市场合 法销售的准入条件。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

截至2026年2月5日收盘，春立医疗(688236)报收于23.13元，上涨0.43%，换手率0.44%，成交量1.27万 手，成交额2937.3万元。 来自交易信息汇总：2月5日主力资金净流入113.92万元，占总成交额3.88%。 来自公司公告汇总：截至2026年1月31日，春立医疗H股与A股注册资本及发行股份总数无变动， H股公众持股量符合上市规则要求。 2月5日主力资金净流入113.92万元，占总成交额3.88%；游资资金净流出33.09万元，占总成交额 1.13%；散户资金净流出80.83万元，占总成交额2.75%。 公司公告汇总H股市场公告 北京市春立正达医疗器械股份有限公司提交截至2026年1月31日的证券变动月报表。公司H股和A股的法 定/注册股本在本月无变动，H股总数为95,140,500股，A股总数为288,428,000股，总注册资本为人民币 383,568,500元。已发行股份中，H股为95,140,500股，无库存股；A股已发行股份为288,428,000股，其中 库存股1,376,851股。公司确认H股公众持股量符合上市规则要求。本月无股份增减变动，所有发行事项 均已获董事会批准并 ...

Group 1 - The stock price of Yingke Medical (300677) closed at 40.94 yuan on February 5, 2026, down by 0.46%, with a turnover rate of 1.23%, a trading volume of 57,100 shares, and a transaction amount of 233 million yuan [1] - On February 5, the net outflow of main funds was 4.5111 million yuan, while the net inflow of speculative funds was 16.974 million yuan, and the net outflow of retail funds was 12.4629 million yuan [2] Group 2 - Yingke Medical announced that it provided a joint liability guarantee of 300 million yuan for its wholly-owned subsidiary, Shandong Yingke Medical Products Co., Ltd., to apply for credit from Huaxia Bank Weifang Branch [1] - The total guarantee balance of the company and its subsidiaries reached 1,616,652.02 million yuan, accounting for 92.89% of the company's most recent audited net assets [1][2] - The guarantee matters have been approved by the board of directors, the board of supervisors, and the shareholders' meeting, with no overdue guarantees and no guarantees for entities outside the consolidated financial statements [1]

截至2026年2月5日收盘，振德医疗(603301)报收于69.95元，下跌0.63%，换手率0.35%，成交量9325.0 手，成交额6513.76万元。 当日关注点 交易信息汇总 资金流向 2月5日主力资金净流入339.93万元，占总成交额5.22%；游资资金净流入558.76万元，占总成交额 8.58%；散户资金净流出898.69万元，占总成交额13.8%。 振德医疗用品股份有限公司于2026年2月4日收到天健会计师事务所出具的《关于变更项目质量复核人的 函》。因工作调整，原项目质量复核人郑传贤先生不再担任，由王文先生接任。王文先生自2011年起成 为中国注册会计师并从事上市公司审计，自2011年起在天健执业，2025年起为公司提供审计服务，近三 年签署或复核多家上市公司审计报告。其具备独立性，未因执业行为受过处罚。本次变更不影响公司 2025年度财务报表及内部控制审计工作的正常进行。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：2月5日主力与游资资金均呈净流入，合计达898.69万元，散户资金净流出 8 ...